Tetracaine from urethral ointment causes false positive amphetamine results by immunoassay

• Published in: Clinical toxicology (Philadelphia, Pa.) Vol. 59; no. 6; pp. 500 - 505
• Main Authors: Wijngaard, Robin, Parra-Robert, Marina, Marés, Lourdes, Escalante, Anna, Salgado, Emilio, González-de-la-Presa, Bernardino, To-Figueras, Jordi, Brunet, Mercè
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 03-06-2021
• Subjects: Amphetamine false positive; cross - reactivity; gas chromatography - mass spectrometry; immunoassay interference; tetracaine; Amphetamine false positive; gas chromatography – mass spectrometry; cross – reactivity; tetracaine; immunoassay interference
• ISSN: 1556-3650; 1556-9519
• DOI: 10.1080/15563650.2020.1834114

Amphetamine urine drug screening by immunoassay is prone to cross-react with other compounds leading to false positive results. Tetracaine is a local anesthetic drug used in the clinical setting as an ointment during urinary catheterization. In our laboratory, tetracaine is often detected by gas chromatography-mass spectrometry in the urine of patients admitted in the emergency department with false positive amphetamine results. The objectives of this study were to investigate if there was cross-reactivity to tetracaine in an amphetamine immunoassay and to retrospectively evaluate the potential contribution of tetracaine to false positive amphetamine results.
An interference study was conducted using negative urine samples spiked with increasing concentrations of tetracaine hydrochloride and analyzed with the CEDIA Amphetamine/Ecstasy immunoassay. Retrospectively, urine samples of patients which yielded positive amphetamine immunoassay results and were analyzed by gas chromatography-mass spectrometry were reviewed (n = 417). The presence of tetracaine and/or other drugs by gas chromatography-mass spectrometry were gathered.
Tetracaine caused false positive amphetamine results by immunoassay (cut-off 1000 µg/L) with a concentration of above 40 mg/L. Retrospective analysis of all positive amphetamine immunoassay samples showed that in 45 out of the 417 (10.8%) urine samples no amphetamine-like derivative was identified by gas chromatography - mass spectrometry. In 37 out of 45 (82.2%) of these false positive cases tetracaine was detected, of whom 59.5% (22/37) had an estimated tetracaine concentration of ≥40 mg/L.
This study confirmed the interference of tetracaine in the CEDIA Amphetamine/Ecstasy immunoassay and that tetracaine may have contributed to around 80% of the false positive amphetamine cases in the urine samples of patients admitted to the emergency department at our institution.